eligibility_summary
Include: Right‑sided metastatic colorectal cancer, measurable disease, RAS/BRAF V600E wild‑type and negative for PIK3CA/PTEN/EGFR(ECD), HER2/MET amplification, ALK/RET/NTRK1 fusions, progressed after bevacizumab, irinotecan (≤3 mo), oxaliplatin, 5‑FU, no prior anti‑EGFR/PD‑1, adequate counts/organ function (Child‑Pugh A, CrCl>50), no ascites, ECOG 0–2, survival >3 mo, consent. Exclude: major thrombotic/bleeding/CV/CNS disease, uncontrolled illness, autoimmune/ID/TB, recent immunosuppression/trial drug, transplant, pregnancy, noncompliance, no contraception, drug allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in refractory right-sided RAS/BRAF wild-type metastatic colorectal cancer tests: cetuximab, toripalimab, and irinotecan. Cetuximab (Erbitux) is a chimeric IgG1 monoclonal antibody against EGFR, it blocks ligand binding and downstream MAPK/ERK and PI3K/AKT signaling and can trigger ADCC, targeting EGFR-expressing tumor cells. Toripalimab (Loqtorzi) is a humanized IgG4 anti–PD-1 immune checkpoint monoclonal antibody, it blocks PD‑1 interaction with PD‑L1/PD‑L2 to restore cytotoxic T‑cell activity. Irinotecan (CPT‑11) is a cytotoxic camptothecin prodrug, SN‑38 inhibits topoisomerase I, causing DNA damage and apoptosis. Targets/pathways: EGFR, PD‑1/PD‑L1 axis on T cells, and DNA replication/Topo I in tumor cells.